Nuveen LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Nuveen LLC purchased 542,018 shares of Regeneron Pharmaceuticals, valued at approximately $343.76 million, representing 0.50% ownership of the company.
• Regeneron reported EPS of $12.89 for the last quarter, exceeding estimates and indicating a 3.6% year-over-year revenue increase.
• The company declared a quarterly dividend of $0.88, with a dividend yield of 0.6%, scheduled for payment on September 3rd.

Nuveen LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 542,018 shares of the biopharmaceutical company's stock, valued at approximately $343,764,000. Nuveen LLC owned 0.50% of Regeneron Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $5.00 during trading hours on Wednesday, hitting $561.55. The company had a trading volume of 1,095,985 shares, compared to its average volume of 986,192. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The firm has a 50 day simple moving average of $539.27 and a 200 day simple moving average of $597.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market capitalization of $59.52 billion, a price-to-earnings ratio of 14.15, a PEG ratio of 1.88 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the firm posted $11.56 EPS. The company's revenue was up 3.6% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analyst Weigh In

A number of research firms have commented on REGN. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Citigroup restated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $835.74.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.